Theravance Biopharma Inc
Latest Theravance Biopharma Inc News and Updates
Highlights of Iridian Asset Management’s holdings: 13G filing
In its recent 13G filing, Iridian Asset Management disclosed the sale of two of its major holdings and amendments to 14 of its prevailing positions.
Understanding the Performance of Merck’s Hospital Acute Care Drugs Noxafil and Cubicin
In 4Q17, Merck’s (MRK) Cubicin reported revenues of $92 million, which was ~23% lower on a YoY (year-over-year) basis.Consumer Must-know: The Baupost Group’s 2Q14 positions
The size of the fund’s U.S. long portfolio increased 48% to $6.14 billion in the second quarter from $4.14 billion in the first quarter. The fund’s top positions include Micron Technology, Idenix Pharmaceuticals, and Viasat.
Why Texas Roadhouse Increased Its Menu Prices
The company increased its menu prices by 1.5% in early December of 2013, and in 2012, it increased menu prices by 2.2%.